The effect of the antiplatelet drug Prasugrel on the interactions between immune cells and the blood clotting cells platelets in patients with cardiovascular disease.
Phase 3
Completed
- Conditions
- AtherosclerosisCardiovascular - Diseases of the vasculature and circulation including the lymphatic system
- Registration Number
- ACTRN12612001157864
- Lead Sponsor
- Capital and Coast District Heath Board
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Vascular population
*Patients on carotid surveillance programme with an identified carotid stenosis
of >50%
*Patient is not on any antiplatelet therapy
Healthy population
*Healthy volunteers aged 18-45
*Not on any cardiovascular medication or immune modulating drugs.
Exclusion Criteria
Acute coronary syndrome within the preceding 3 months.
Intercurrent illness
Inability to provide written informed consent.
Compliance with follow-up likely to be inadequate
Known bleeding disorder
Platelet dysfunction
Recent surgery within 3 months
Pregnancy
Allergy to Prasugrel
Administration of antiplatelet agent of NSAIDs in last 2 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method